Reponen, Elina J. http://orcid.org/0000-0002-2455-4820
Ueland, Thor
Rokicki, Jaroslav
Bettella, Francesco
Aas, Monica
Werner, Maren C. F.
Dieset, Ingrid
Steen, Nils E.
Andreassen, Ole A.
Tesli, Martin
Funding for this research was provided by:
Norges Forskningsråd (#213837, #223273, #217776)
Helse Sør-Øst RHF (#2017-112, #2016-064)
Helse Vest Regionalt Helseføretak (#91141)
Stiftelsen Kristian Gerhard Jebsen (SKGJ-2011-36)
H2020 European Research Council (# 847776, CoMorMent)
University of Oslo
Article History
Received: 11 April 2022
Accepted: 20 February 2023
First Online: 5 May 2023
Declarations
:
: O. A. Andreassen has received speaker’s honorarium from Lundbeck and is a consultant for HealthLytix. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: The TOP Study was approved by the Regional Committee for Medical Research Ethics and the Norwegian Data Inspectorate. The biobank was approved by the Norwegian Directorate of Health. All participants have given written informed consent. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees of human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.